Immuneering Corporation (NASDAQ:IMRX) Receives Average Recommendation of “Moderate Buy” from Analysts

Shares of Immuneering Corporation (NASDAQ:IMRX) have been assigned a consensus recommendation of “Moderate Buy” from the seven ratings firms that are presently covering the stock, Marketbeat reports. One analyst has rated the stock with a sell recommendation, five have given a buy recommendation and one has issued a strong buy recommendation on the company. The average 1-year price objective among brokerages that have covered the stock in the last year is $16.50.

IMRX has been the subject of a number of recent research reports. Wall Street Zen downgraded shares of Immuneering from a “hold” rating to a “sell” rating in a report on Saturday, December 20th. Weiss Ratings reiterated a “sell (d-)” rating on shares of Immuneering in a research report on Monday, December 29th. Chardan Capital reissued a “buy” rating and set a $20.00 price target on shares of Immuneering in a research report on Thursday, November 13th. Leerink Partners assumed coverage on Immuneering in a research note on Friday, October 31st. They set an “outperform” rating and a $15.00 price objective on the stock. Finally, Mizuho set a $12.00 target price on Immuneering in a research report on Wednesday, October 29th.

Immuneering Price Performance

Shares of NASDAQ IMRX opened at $4.63 on Friday. The firm has a market cap of $298.96 million, a price-to-earnings ratio of -2.60 and a beta of 0.48. The stock’s fifty day moving average price is $5.99 and its two-hundred day moving average price is $5.87. Immuneering has a one year low of $1.10 and a one year high of $10.08.

Immuneering (NASDAQ:IMRX) last announced its earnings results on Wednesday, November 12th. The company reported ($0.38) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.37) by ($0.01). On average, equities analysts anticipate that Immuneering will post -1.86 earnings per share for the current fiscal year.

Insider Activity

In other news, Director Thomas J. Schall acquired 21,645 shares of Immuneering stock in a transaction on Thursday, January 15th. The shares were purchased at an average cost of $4.67 per share, for a total transaction of $101,082.15. Following the completion of the purchase, the director directly owned 74,530 shares of the company’s stock, valued at approximately $348,055.10. This represents a 40.93% increase in their position. The transaction was disclosed in a filing with the SEC, which is available through the SEC website. Also, Director Peter Feinberg bought 20,000 shares of the firm’s stock in a transaction on Monday, January 12th. The stock was purchased at an average cost of $4.35 per share, for a total transaction of $87,000.00. Following the completion of the acquisition, the director owned 135,441 shares in the company, valued at approximately $589,168.35. This trade represents a 17.32% increase in their ownership of the stock. The disclosure for this purchase is available in the SEC filing. Insiders have purchased 51,819 shares of company stock valued at $234,472 in the last ninety days. 22.90% of the stock is currently owned by company insiders.

Institutional Inflows and Outflows

Several institutional investors have recently added to or reduced their stakes in IMRX. Sanofi acquired a new stake in shares of Immuneering in the 3rd quarter valued at $18,960,000. Vanguard Group Inc. raised its holdings in shares of Immuneering by 128.5% during the 3rd quarter. Vanguard Group Inc. now owns 2,415,244 shares of the company’s stock worth $16,907,000 after buying an additional 1,358,322 shares in the last quarter. Citadel Advisors LLC bought a new stake in shares of Immuneering during the 3rd quarter worth $6,602,000. Blue Owl Capital Holdings LP acquired a new stake in Immuneering in the third quarter valued at about $3,850,000. Finally, Monashee Investment Management LLC bought a new position in Immuneering in the third quarter valued at about $2,100,000. 67.65% of the stock is currently owned by institutional investors and hedge funds.

About Immuneering

Immuneering (Nasdaq: IMRX) is a clinical-stage biopharmaceutical company leveraging artificial intelligence and its proprietary RABIT (Repurposing and Accelerating Biotechnology Tools) platform to design and optimize small-molecule and peptide therapies. By analyzing large-scale biomedical datasets, Immuneering’s machine learning algorithms identify novel drug–target interactions, repurpose existing drug scaffolds and accelerate lead candidate selection. The company’s AI-driven approach aims to reduce development timelines and improve therapeutic profiles in areas of high unmet medical need.

The company’s lead program, IRX-2, is a small-molecule candidate currently in Phase 2 clinical trials for the treatment of painful diabetic peripheral neuropathy.